Healthcare >> CEO Interviews >> October 12, 2001
MARK MCDADE is Chief Executive Officer of Signature BioScience,
Inc. He joined Signature as the company's first full-time CEO in
December 2000, leaving his position as President and Chief
Operating Officer of Corixa Corporation subsequent to completion
of the Coulter transaction. At Corixa, he was a co-founder of the
company, and remains on the Board of Directors. Prior to Corixa,
Mr. McDade served as the Chief Operating Officer of Boehringer
Mannheim Therapeutics, the worldwide pharmaceutical division of
Corange Ltd. His prior experience includes various management
positions with Sandoz Ltd. Mr. McDade also serves on the Board of
Directors of Valentis, Inc. of Burlingame, CA and Akceli, Inc. of
Cambridge, MA. Mr. McDade graduated from Dartmouth College and
received his MBA from Harvard University. Profile
TWST: May we begin with a brief historical sketch of SignatureBioScience, and then an overview of what the company is doing at the
present time?
Mr. McDade: Signature was formed in late 1998